Abstract
Despite numerous reports demonstrating mitochondrial abnormalities associated with amyotrophic lateral sclerosis (ALS), the role of mitochondrial dysfunction in the disease onset and progression remains unknown. The intrinsic mitochondrial apoptotic program is activated in the central nervous system of mouse models of ALS harboring mutant superoxide dismutase 1 protein. This is associated with the release of cytochrome-c from the mitochondrial intermembrane space and mitochondrial swelling. However, it is unclear if the observed mitochondrial changes are caused by the decreasing cellular viability or if these changes precede and actually trigger apoptosis. This article discusses the current evidence for mitochondrial involvement in familial and sporadic ALS and concludes that mitochondria is likely to be both a trigger and a target in ALS and that their demise is a critical step in the motor neuron death.
Similar content being viewed by others
References
Rowland L. P. (1998) Diagnosis of amyotrophic lateral sclerosis. J. Neurol. Sci. 160 (Suppl 1), S6-S24.
Brown R. H. Jr. (1995) Amyotrophic lateral sclerosis: recent insights from genetics and transgenic mice. Cell 80, 687–692.
Fridovich I. (1986) Superoxide dismutases. Adv. Enzymol. Relat. Areas Mol. Biol. 58, 61–97.
Rosen D. R. (1993) Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature 364, 362.
Culotta V.C., Klomp L. W., Strain J., Casareno R. L., Krems B., and Gitlin J. D. (1997) The copper chaperone for superoxide dismutase. J. Biol. Chem. 272, 23,469–23,472.
Wong P. C., Waggoner D., Subramaniam J. R., et al. (2000) Copper chaperone for superoxide dismutase is essential to activate mammalian Cu/Zn superoxide dismutase. Proc. Natl. Acad. Sci. USA 97, 2886–2891.
Gurney M. E. (1994) Transgenic-mouse model of amyotrophic lateral sclerosis. N. Engl. J. Med. 331, 1721,1722
Dal Canto M. C. and Gurney M. E. (1994) Development of central nervous system pathology in a murine transgenic model of human amyotrophic lateral sclerosis. Am. J. Pathol. 145, 1271–1279.
Dal Canto M. C. and Gurney M. E. (1995) Neuropathological changes in two lines of mice carrying a transgene for mutant human Cu,Zn SOD, and in mice overexpressing wild type human SOD: a model of familial amyotrophic lateral sclerosis (FALS). Brain Res. 676, 25–40.
Gong Y. H., Parsadanian A. S., Andreeva A., Snider W. D., and Elliott J. L. (2000) Restricted expression of G86R Cu/Zn superoxide dismutase in astrocytes results in astrocytosis but does not cause motoneuron degeneration. J. Neurosci. 20, 660–665.
Lino M. M., Schneider C., and Caroni P. (2002) Accumulation of SOD1 mutants in postnatal motoneurons does not cause motoneuron pathology or motoneuron disease. J. Neurosci. 22, 4825–4832.
Xu Z. (2000) Mechanism and treatment of motoneuron degeneration in ALS: what have SOD1 mutants told us? Amyotroph. Lateral Scler. Other Motor Neuron Disord. 1, 225–234.
Kong J. and Xu Z. (1998) Massive mitochondrial degeneration in motor neurons triggers the onset of amyotrophic lateral sclerosis in mice expressing a mutant SOD1. J. Neurosci. 18, 3241–3250.
Kato S., Saeki Y., Aoki M., et al. (2004) Histological evidence of redox system breakdown caused by superoxide dismutase 1 (SOD1) aggregation is common to SOD1-mutated motor neurons in humans and animal models. Acta. Neuropathol. (Berl.) 107, 149–158.
Wood J. D., Beaujeux T. P., and Shaw P. J. (2003) Protein aggregation in motor neurone disorders. Neuropathol. Appl. Neurobiol. 29, 529–545.
Julien J. P. (1995) A role for neurofilaments in the pathogenesis of amyotrophic lateral sclerosis. Biochem. Cell Biol. 73, 593–597.
Mattiazzi M., D'Aurelio M., Gajewski C. D., et al. (2002) Mutated human SOD1 causes dysfunction of oxidative phosphorylation in mitochondria of transgenic mice. J. Biol. Chem. 277, 29,626–29,633.
Przedborski S. (2004) Programmed cell death in amyotrophic lateral sclerosis: a mechanism of pathogenic and therapeutic importance. Neurologist 10, 1–7.
Cox P. A., Banack S. A., and Murch S. J. (2003) Biomagnification of cyanobacterial neurotoxins and neurodegenerative disease among the Chamorro people of Guam. Proc. Natl. Acad. Sci. USA 100, 13,380–13,383.
Kruman I. I. and Mattson M. P. (1999) Pivotal role of mitochondrial calcium uptake in neural cell apoptosis and necrosis. J. Neurochem. 72, 529–540.
Hirano A. (1996) Neuropathology of ALS: an overview. Neurology 47, S63-S66.
Chung M. J. and Suh Y. L. (2002) Ultrastructural changes of mitochondria in the skeletal muscle of patients with amyotrophic lateral sclerosis. Ultrastruct. Pathol. 26, 3–7.
Wong P. C., Pardo C. A., Borchelt D. R., et al. (1995) An adverse property of a familial ALS-linked SOD1 mutation causes motor neuron disease characterized by vacuolar degeneration of mitochondria. Neuron 14, 1105–1116.
Bendotti C., Calvaresi N., Chiveri L., et al. (2001) Early vacuolization and mitochondrial damage in motor neurons of FALS mice are not associated with apoptosis or with changes in cytochrome oxidase histochemical reactivity. J. Neurol. Sci. 191, 25–33.
Higgins C. M., Jung C., and Xu Z. (2003) ALS-associated mutant SOD1G93A causes mitochondrial vacuolation by expansion of the intermembrane space and by involvement of SOD1 aggregation and peroxisomes. BMC Neurosci. 4, 16.
Jaarsma D., Rognoni F., van Duijn W., Verspaget H. W., Haasdijk E. D., and Holstege J. C. (2001) CuZn superoxide dismutase (SOD1) accumulates in vacuolated mitochondria in transgenic mice expressing amyotrophic lateral sclerosis-linked SOD1 mutations. Acta. Neuropathol. (Berl.) 102, 293–305.
Xu Z., Jung C., Higgins C., Levine J., and Kong J. (2004) Mitochondrial degeneration in amyotrophic lateral sclerosis. J. Bioenerg. Biomembr. 36, 395–399.
Kirkinezos I. G., Bacman S. R., Hernandez D., et al. (2005) Cytochrome c association with the inner mitochondrial membrane is impaired in the CNS of G93A-SOD1 mice. J. Neurosci. 25, 164–172.
Bowling A. C., Schulz J. B., Brown R. H. Jr., and Beal M. F. (1993) Superoxide dismutase activity, oxidative damage, and mitochondrial energy metabolism in familial and sporadic amyotrophic lateral sclerosis. J. Neurochem. 61, 2322–2325.
Browne S. E., Bowling A. C., Baik M. J., Gurney M., Brown R. H. Jr., and Beal M. F. (1998) Metabolic dysfunction in familial, but not sporadic, amyotrophic lateral sclerosis. J. Neurochem. 71, 281–287.
Wiedemann F. R., Winkler K., Kuznetsov A. V., et al. (1998) Impairment of mitochondrial function in skeletal muscle of patients with amyotrophic lateral sclerosis. J. Neurol. Sci. 156, 65–72.
Borthwick G. M., Johnson M. A., Ince P. G., Shaw P. J., and Turnbull D. M. (1999) Mitochondrial enzyme activity in amyotrophic lateral sclerosis: implications for the role of mitochondria in neuronal cell death. Ann. neurol. 46, 787–790.
Vielhaber S., Kunz D., Winkler K., et al. (2000) Mitochondrial DNA abnormalities in skeletal muscle of patients with sporadic amyotrophic lateral sclerosis. Brain 123 (Pt. 7), 1339–1348.
Echaniz-Laguna A., Zoll J., Ribera F., et al. (2002) Mitochondrial respiratory chain function in skeletal muscle of ALS patients. Ann. Neurol. 52, 623–627.
Wiedemann F. R., Manfredi G., Mawrin C., Beal M. F., and Schon E. A. (2002) Mitochondrial DNA and respiratory chain function in spinal cords of ALS patients. J. Neurochem. 80, 616–625.
Jung C., Higgins C. M., and Xu Z. (2002) Mitochondrial electron transport chain complex dysfunction in a transgenic mouse model for amyotrophic lateral sclerosis. J. Neurochem. 83, 535–545.
Menzies F. M., Cookson M. R., Taylor R. W., et al. (2002) Mitochondrial dysfunction in a cell culture model of familial amyotrophic lateral sclerosis. Brain 125, 1522–1533.
Swerdlow R. H., Parks J. K., Cassarino D. S., et al. (1998) Mitochondria in sporadic amyotrophic lateral sclerosis. Exp. Neurol. 153, 135–142.
Gajewski C. D., Lin M. T., Cudkowicz M. E., Beal M. F., and Manfredi G. (2003) Mitochondrial DNA from platelets of sporadic ALS patients restores normal respiratory functions in rho(0) cells. Exp. Neurol. 179, 229–235.
Ro L. S., Lai S. L., Chen C. M., and Chen S. T. (2003) Deleted 4977-bp mitochondrial DNA mutation is associated with sporadic amyotrophic lateral sclerosis: a hospital-based case-control study. Muscle Nerve 28, 737–743.
Dhaliwal G. K. and Grewal R. P. (2000) Mitochondrial DNA deletion mutation levels are elevated in ALS brains. Neuroreport 11, 2507–2509.
Menzies F. M., Ince P. G., and Shaw P. J. (2002) Mitochondrial involvement in amyotrophic lateral sclerosis. Neurochem. Int. 40, 543–551.
Mawrin C., Kirches E., Krause G., et al. (2004) Single-cell analysis of mtDNA deletion levels in sporadic amyotrophic lateral sclerosis. Neuroreport 15, 939–943.
Rosen D. R., Sapp P., O'Regan J., et al. (1994) Genetic linkage analysis of familial amyotrophic lateral sclerosis using human chromosome 21 microsatellite DNA markers. Am. J. Med. Genet. 51, 61–69.
Mancuso M., Conforti F. L., Rocchi A., et al. (2004) Could mitochondrial haplogroups play a role in sporadic amyotrophic lateral sclerosis? Neurosci. Lett. 371, 158–162.
Xu G. P., Dave K. R., Moraes C. T., et al. (2001) Dysfunctional mitochondrial respiration in the wobbler mouse brain. Neurosci. Lett. 300, 141–144.
Wei Y. H., Lu C. Y., Lee H. C., Pang C. Y., and Ma Y. S. (1998) Oxidative damage and mutation to mitochondrial DNA and age-dependent decline of mitochondrial respiratory function. Ann. NY Acad. Sci. 854, 155–170.
Shibata N., Nagai R., Uchida K., et al. (2001) Morphological evidence for lipid peroxidation and protein glycoxidation in spinal cords from sporadic amyotrophic lateral sclerosis patients. Brain Res. 917, 97–104.
Simpson E. P., Henry Y. K., Henkel J. S., Smith R. G., and Appel S. H. (2004) Increased lipid peroxidation in sera of ALS patients: a potential biomarker of disease burden. Neurology 62, 1758–1765.
Siciliano G., D'Avino C., Del Corona A., et al. (2002) Impaired oxidative metabolism and lipid peroxidation in exercising muscle from ALS patients. Amyotroph. Lateral Scler. Other Motor Neuron Disord. 3, 57–62.
Carri M. T., Ferri A., Cozzolino M., Calabrese L., and Rotilio G. (2003) Neurodegeneration in amyotrophic lateral sclerosis: the role of oxida tive stress and altered homeostasis of metals. Brain Res. Bull. 61, 365–374.
Subramaniam J. R., Lyons W. E., Liu J., et al. (2002) Mutant SOD1 causes motor neuron disease independent of copper chaperone-mediated copper loading. Nat. Neurosci. 5, 301–307.
Bush A. I. (2002) Is ALS caused by an altered oxidative activity of mutant superoxide dismutase? Nat. Neurosci. 5, 919; author reply 919–920.
Liu D., Wen J., Liu J., and Li L. (1999) The roles of free radicals in amyotrophic lateral sclerosis: reactive oxygen species and elevated oxidation of protein, DNA, and membrane phospholipids. FASEB J. 13, 2318–2328.
Wootz H., Hansson I., Korhonen L., Napankangas U., and Lindholm D. (2004) Caspase-12 cleavage and increased oxidative stress during motoneuron degeneration in transgenic mouse model of ALS. Biochem. Biophys. Res. Commun. 322, 281–286.
Hall E. D., Andrus P. K., Oostveen J. A., Fleck T. J., and Gurney M. E. (1998) Relationship of oxygen radical-induced lipid peroxidative damage to disease onset and progression in a transgenic model of familial ALS. J. Neurosci. Res. 53, 66–77.
Garcia Fernandez M. I., Ceccarelli, D., and Muscatello U. (2004) Use of the fluorescent dye 10-N-nonyl acridine orange in quantitative and location assays of cardiolipin: a study on different experimental models. Anal. Biochem. 328, 174–180.
Blaauwgeers H. G., Vianney de Jong J. M., Verspaget H. W., van den Berg F. M., and Troost D. (1996) Enhanced superoxide dismutase-2 immunoreactivity of astrocytes and occasional neurons in amyotrophic lateral sclerosis. J. Neurol. Sci. 140, 21–29.
Liu Y., Brooks B. R., Taniguchi N., and Hartmann H. A. (1998) CuZnSOD and MnSOD immunoreactivity in brain stem motor neurons from amyotrophic lateral sclerosis patients. Acta. Neurophathol. (Berl.) 95, 63–70.
McEachern G., Kassovska-Bratinova S., Raha S., et al. (2000) Manganese superoxide dismutase levels are elevated in a proportion of amyotrophic lateral sclerosis patient cell lines. Biochem. Biophys. Res. Commun. 273, 359–363.
Radunovic A., Porto W. G., Zeman S., and Leigh P. N. (1997) Increased mitochondrial superoxide dismutase activity in Parkinson's disease but not amyotrophic lateral sclerosis motor cortex. Neurosci. Lett. 239, 105–108.
Paradies G., Petrosillo G., Pistolese M., and Ruggiero F. M. (2000) The effect of reactive oxygen species generated from the mitochondrial electron transport chain on the cytochrome c oxidase activity and on the cardiolipin content in bovine heart submitochondrial particles. FEBS Lett. 466, 323–326.
Crapo J. D., Oury T., Rabouille C., Slot J. W., and Chang L. Y. (1992) Copper, zinc superoxide dismutase is primarily a cytosolic protein in human cells. Proc. Natl. Acad. Sci. USA 89, 10,405–10,409.
Kira Y., Sato E. F., and Inoue M. (2002) Association of Cu, Zn-type superoxide dismutase with mitochondria and peroxisomes. Arch. Biochem. Biophys. 399, 96–102.
Fridovich I. (1997) Superoxide anion radical (O2-.), superoxide dismutases, and related matters. J. Biol. Chem. 272, 18,515–18,517.
Valentine J. S., Doucette P. A., and Potter S. Z. (2004) Copper-Zinc Superoxide Dismutase and Amyotrophic Lateral Sclerosis. Annu. Rev. Biochem. 74, 563–593.
Weisiger R. A., and Fridovich I. (1973) Mitochondrial superoxide simutase. Site of synthesis and intramitochondrial localization. J. Biol. Chem. 248, 4793–4796.
Tyler D. D. (1975) Polarographic assay and intracellular distribution of superoxide dismutase in rat liver. Biochem. J. 147, 493–504.
Okado-Matsumoto A. and Fridovich I. (2001) Subcellular distribution of superoxide dismutases (SOD) in rat liver: Cu,Zn-SOD in mitochondria. J. Biol. Chem. 276, 38,388–38,393.
Geller B. L. and Winge D. R. (1982) Rat liver Cu,Zn-superoxide dismutase. Subcellular location in lysosomes. J. Biol. Chem. 257, 8945–8952.
Higgins C. M., Jung C., Ding H., and Xu Z. (2002) Mutant Cu, Zn superoxide dismutase that causes motoneuron degeneration is present in mitochondria in the CNS. J. Neurosci. 22, RC215.
Sturtz L. A., Diekert K., Jensen L. T., Lill R., and Culotta V. C. (2001) A fraction of yeast Cu,Zn-superoxide dismutase and its metallochaperone, CCS, localize to the intermembrane space of mitochondria. A physiological role for SOD1 in guarding against mitochondrial oxidative damage. J. Biol. Chem. 276, 38,084–38,089.
Vijayvergiya C., Beal M. F., Buck J., and Manfredi G. (2005) Mutant superoxide dismutase 1 forms aggregates in the brain mitochondrial matrix of amyotrophic lateral sclerosis mice. J. Neurosci. 25, 2463–2470.
Liu J., Lillo C., Jonsson P. A., et al. (2004) Toxicity of familial ALS-linked SOD1 mutants from selective recruitment to spinal mitochondria. Neuron 43, 5–17.
Pasinelli P., Belford M. E., Lennon N., et al. (2004) Amyotrophic lateral sclerosis-associated SOD1 mutant proteins bind and aggregate with Bcl-2 in spinal cord mitochondria. Neuron 43, 19–30.
Bruijn L. I., Houseweart M. K., Kato S., et al. (1998) Aggregation and motor neuron toxicity of an ALS-linked SOD1 mutant independent from wild-type SOD1. Science 281, 1851–1854.
Schwartz A. L. and Ciechanover A. (1999) The ubiquitin-proteasome pathway and pathogenesis of human diseases. Annu. Rev. Med. 50, 57–74.
Leigh P. N., Whitwell H., Garofalo O., et al. (1991) Ubiquitin-immunoreactive intraneuronal inclusions in amyotrophic lateral sclerosis. Morphology, distribution, and specificity. Brain 114 (Pt. 2), 775–788.
Durham H. D., Roy J., Dong L., and Figlewicz D. A. (1997) Aggregation of mutant Cu/Zn superoxide dismutase proteins in a culture model of ALS. J. Neuropathol. Exp. Neurol. 56, 523–530.
Dal Canto M. C. and Gurney M. E. (1997) A low expressor line of transgenic mice carrying a mutant human Cu,Zn superoxide dismutase (SOD1) gene develops pathological changes that most closely resemble those in human amyotrophic lateral sclerosis. Acta. Neuropathol. (Berl.) 93, 537–550.
Jonsson P. A., Ernhill K., Andersen P. M., et al. (2004) Minute quantities of misfolded mutant superoxide dismutase-1 cause amyotrophic lateral sclerosis. Brain 127, 73–88.
Johnston J. A., Dalton M. J., Gurney M. E., and Kopito R. R. (2000) Formation of high molecular weight complexes of mutant Cu,Zn-superoxide dismutase in a mouse model for familial amyotrophic lateral sclerosis. Proc. Natl. Acad. Sci. USA 97, 12,571–12,576.
Sasaki S., Warita H., Murakami T., et al. (2004) Ultrastructural study of aggregates in the spinal cord of transgenic mice with a G93A mutant SOD1 gene. Acta. Neuropathol. (Berl.) 109, 247–255.
Tobisawa S., Hozumi Y., Arawaka S., et al. (2003) Mutant SOD1 linked to familial amyotrophic lateral sclerosis, but not wild-type SOD1, induces ER stress in COS7 cells and transgenic mice. Biochem. Biophys. Res. Commun. 303, 496–503.
Hartl F. U. (1996) Molecular chaperones in cellular protein folding. Nature 381, 571–579.
Ohtsuka K. and Suzuki T. (2000) Roles of molecular chaperones in the nervous system. Brain Res. Bull. 53, 141–146.
Bruening W., Roy J., Giasson B., Figlewicz D. A., Mushynski W. E., and Durham H. D. (1999) Up-regulation of protein chaperones preserves viability of cells expressing toxic Cu/Zn-superoxide dismutase mutants associated with amyotrophic lateral sclerosis. J. Neurochem. 72, 693–699.
Takeuchi H., Kobayashi Y., Yoshihara T., et al. (2002) Hsp70 and Hsp40 improve neurite out-growth and suppress intracytoplasmic aggregate formation in cultured neuronal cells expressing mutant SOD1. Brain Res. 949, 11–22.
Maatkamp A., Vlug A., Haasdijk E., Troost D., French P. J., and Jaarsma D. (2004) Decrease of Hsp25 protein expression precedes degeneration of motoneurons in ALS-SOD1 mice. Eur. J. Neurosci. 20, 14–28.
Tummala H., Jung C., Tiwari A., Higgins C. M., Hayward L. J., and Xu Z. (2005) Inhibition of chaperone activity is a shared property of several Cu, Zn superoxide dismutase mutants that cause amyotrophic lateral sclerosis. J. Biol. Chem. 280, 17,725–17,731.
Neupert W. and Brunner M. (2002) The protein import motor of mitochondria. Nat. Rev. Mol. Cell. Biol. 3, 555–565.
Okado-Matsumoto A. and Fridovich I. (2002) Amyotrophic lateral sclerosis: a proposed mechanism. Proc. Natl. Acad. Sci. USA 99, 9010–9014.
Takeuchi H., Kobayashi Y., Ishigaki S., Doyu M., and Sobue G. (2002) Mitochondrial localization of mutant superoxide dismutase 1 triggers caspase-dependent cell death in a cellular model of familial amyotrophic lateral sclerosis. J. Biol. Chem. 277, 50,966–50,972.
Guegan C., Vila M., Rosoklija G., Hays A. P., and Przedborski S. (2001) Recruitment of the mitochondrial-dependent apoptotic pathway in amyotrophic lateral sclerosis. J. Neurosci. 21, 6569–6576.
Martin L. J. (1999) Neuronal death in amyotrophic lateral sclerosis is apoptosis: possible contribution of a programmed cell death mechanism. J. Neuropathol. Exp. Neurol. 58, 459–471.
Vukosavic S., Dubois-Dauphin M., Romero N., and Przedborski S. (1999) Bax and Bcl-2 interaction in a transgenic mouse model of familial amyotrophic lateral sclerosis. J. Neurochem. 73, 2460–2468.
Vukosavic S., Stefanis L., Jackson-Lewis V., et al. (2000) Delaying caspase activation by Bcl-2: A clue to disease retardation in a transgenic mouse model of amyotrophic lateral sclerosis. J. Neurosci. 20, 9119–9125.
Inoue H., Tsukita K., Iwasato T., et al. (2003) The crucial role of caspase-9 in the disease progression of a transgenic ALS mouse model. EMBO J. 22, 6665–6674.
Cassina A. M., Hodara R., Souza J. M., et al. (2000) Cytochrome c nitration by peroxynitrite. J. Biol. Chem. 275, 21,409–21,415.
Hoch F. L. (1992) Cardiolipins and biomembrane function. Biochim. Biophys. Acta. 1113, 71–133.
Shidoji Y., Hayashi K., Komura S., Ohishi N., and Yagi K. (1999) Loss of molecular interaction between cytochrome c and cardiolipin due to lipid peroxidation. Biochem. Biophys. Res. Commun. 264, 343–347.
Nomura K., Imai H., Koumura T., Kobayashi T., and Nakagawa Y. (2000) Mitochondrial phospholipid hydroperoxide glutathione peroxidase inhibits the release of cytochrome c from mitochondria by suppressing the peroxidation of cardiolipin in hypoglycaemia-induced apoptosis. Biochem. J. 351, 183–193.
Kirkland R. A., Adibhatla R. M., Hatcher J. F., and Franklin J. L. (2002) Loss of cardiolipin and mitochondria during programmed neuronal death: evidence of a role for lipid peroxidation and autophagy. Neuroscience 115, 587–602.
Iverson S. L. and Orrenius S. (2004) The cardiolipin-cytochrome c interaction and the mitochondrial regulation of apoptosis. Arch. Biochem. Biophys. 423, 37–46.
Nakagawa Y. (2004) Initiation of apoptotic signal by the peroxidation of cardiolipin of mitochondria. Ann. NY Acad. Sci. 1011, 177–184.
Perry T. L., Hansen S., and Jones K. (1987) Brain glutamate deficiency in amyotrophic lateral sclerosis. Neurology 37, 1845–1848.
Tsai G. C., Stauch-Slusher B., Sim L., et al. (1991) Reductions in acidic amino acids and N-acetylaspartylglutamate in amyotrophic lateral sclerosis CNS. Brain Res. 556, 151–156.
Rothstein J. D., Tsai G., Kuncl R. W., et al. (1990) Abnormal excitatory amino acid metabolism in amyotrophic lateral sclerosis. Ann. Neurol. 28, 18–25.
Shaw P. J., R. M. Chinnery, and P. G. Ince. (1994) Non-NMDA receptors in motor neuron disease (MND): a quantitative autoradiographic study in spinal cord and motor cortex using [3H]CNQX and [3H]kainate. Brain Res. 655, 186–194.
Rothstein J. D., Van Kammen M., Levey A. I., Martin L. J., and Kuncl R. W. (1995) Selective loss of glial glutamate transporter GLT-1 in amyotrophic lateral sclerosis. Ann. Neurol. 38, 73–84.
Bruijn L. I., Becher M. W., Lee M. K., et al. (1997) ALS-linked SOD1 mutant G85R mediates damage to astrocytes and promotes rapidly progressive disease with SOD1-containing inclusions. Neuron 18, 327–338.
Guo Z., Kindy M. S., Kruman I., and Mattson M. P. (2000) ALS-linked Cu/Zn-SOD mutation impairs cerebral synaptic glucose and giutamate transport and exacerbates ischemic brain injury. J. Cereb. Blood Flow Metab. 20, 463–468.
Lin C. L., Bristol L. A., Jin L., et al. (1998) Aberrant RNA processing in a neurodegenerative disease: the cause for absent EAAT2, a glutamate transporter, in amyotrophic lateral sclerosis. Neuron 20, 589–602.
Meyer T., Fromm A., Munch C., et al. (1999) The RNA of the glutamate transporter EAA12 is variably spliced in amyotrophic lateral sclerosis and normal individuals. J. Neurol. Sci. 170, 45–50.
Honig L. S., Chambliss D. D., Bigio E. H., Carroll S. L., and Elliott J. L. (2000) Glutamate transporter EAAT2 splice variants occur not only in ALS, but also in AD and controls. Neurology 55, 1082–1088.
Health P. R. and Shaw P. J. (2002) Update on the glutamatergic neurotransmitter system and the role of exicitoxicity in amyotrophic lateral sclerosis. Muscle Nerve 26, 438–458.
Howland D. S., Liu J., She Y., t al. (2002) Focal loss of the glutamate transporter EAAT2 in a transgenic rat model of SOD1 mutant-mediated amyotrophic lateral sclerosis (ALS). Proc. Natl. Acad. Sci. USA 99, 1604–1609.
Kruman I. I., Pedersen W. A., Springer J. E., and Mattson M. P. (1999b). ALS-linked Cu/Zn-SOD mutation increases vulnerability of motor neurons to excitotoxicity by a mechanism involving increased oxidative stress and perturbed calcium homeostasis. Exp. Neurol. 160, 28–39.
Hollmann M. and Heinemann S. (1994) Cloned glutamate receptors. Annu. Rev. Neurosci. 17, 31–108.
Kawahara Y., Ito K., Sun H., Aizawa H., Kanazawa I., and Kwak S. (2004) Glutamate receptors: RNA editing and death of motor neurons. Nature 427, 801.
Tateno M., Sadakata H., Tanaka M., et al. (2004) Calcium-permeable AMPA receptors promote misfolding of mutant SOD1 protein and development of amyotrophic lateral sclerosis in a transgenic mouse model. Hum. Mol. Genet. 13, 2183–2196.
Ince P., Stout N., Shaw P., et al. (1993) Parval-bumin and calbindin D-28k in the human motor sytem and in motor neuron disease. Neuropathol. Appl. Neurobiol. 19, 291–299.
Carri M. T., Ferri A., Battistoni A., et al. (1997) Expression of a Cu, Zn superoxide dismutase typical of familial amyotrophic lateral sclerosis induces mitochondrial alteration and increase of cytosolic Ca2+ concentration in transfected neuroblastoma SH-SY5Y cells. FEBS Lett. 414, 365–368.
Siklos L., Engelhardt J, Harati, Y., Smith R. G., Joo F., and Appel S. H. (1996) Ultrastrutural evidence for altered calcium in motor nerve terminals in amyotropic lateral sclerosis. Ann. Neurol. 39, 203–216.
David G., Barrett J. N., and Barrett E. F. (1998) Evidence that mitochondria buffer physiological Ca2+ loads in lizard motor nerve terminals. J. Physiol. 509 (Pt 1), 59–65.
Vila L., Barrett E. F., and Barrett J. N (2003) Stimulation-induced mitochondrial [Ca2+] elevations in mouse motor terminals: comparison of wild-type with SOD1-G93A. J. Physiol. 549, 719–728.
Julien J. P. and Beaulieu J. M. (2000) Cytoskeletal abnormalities in amyotrophic lateral sclerosis: beneficial or detrimental effects? J. Neurol. Sci. 180, 7–14.
Kanekura K., Hashimoto Y., Niikura T., Aiso S., Matsuoka M., and Nishimoto I. (2004) Alsin, the product ALS2 gene, suppresses SOD1 mutant neurotoxicity through RhoGEF domain by interacting with SOD1 mutants. J. Biol. Chem. 279, 19,247–19,256.
Yang Y. Hentati A., Deng H. X., et al. (2001) The gene encoding alsin, a protein with three guanine-nucleotide exchange factor domains, is mutated in a form of recessive amyotrophic lateral sclerosis. Nat. Genet. 29, 160–165.
Julien J. P., Millecamps S., and Kriz J. (2005) Cytoskeletal defects in amyotrophic lateral sclerosis (motor neuron disease). Novartis Found Sympt. 264, 183–192; discussion 192–196, 227–230.
Takamiya R., Takahashi M., Park Y. S., et al. (2005) Overexpression of mutated Cu, Zn-SOD in neuroblastoma cells results in cytoskeletal change. Am. J. Physiol. Cell Physiol. 288, C253-C259.
Kriz J., Meier J., Julien J. P., and Padjen A. L. (2000) Altered ionic conductances in axons of transgenic mouse expressing the human neurofilament heavy gene: A mouse model of amyotrophic lateral sclerosis. Exp. Neurol. 163, 414–421.
Wong N. K., He B. P., and Strong M. J. (2000) Characterization of neuronal intermediate filament protein expression in cervical spinal motor neurons in sporadic amyotrophic lateral sclerosis (ALS). J. Neuropathol. Exp. Neurol. 59, 972–982.
Zhang B., Tu P., Abtahian F., Trojanowski J. Q., and Lee V. M. (1997) Neurofilaments and orthograde transport are reduced in ventral root axons of transgenic mice that express human SOD1 with a G93A mutation. J. Cell Biol. 139, 1307–1315.
Morris R. L. and Hollenbeck P. J. (1995) Axonal transport of mitochondrial along microtubules and F-actin in living vertebrate neurons. J. Cell Biol. 131, 1315–1326.
Sasaki S., and Iwata M. (1996) Impariment of fast axonal transport in the proximal axons of anterior horn neurons in amyotrophic lateral sclerosis. Neurology 47, 535–540.
Santel A. and Fuller M. T. (2001) Control of mitochondrial morphology by a human mitofusin. J. Cell Sci. 114, 867–874.
Legros E., Lombes A., Frachon P., and Rojo M. (2002) Mitchondrial fusion in human cells is efficient, requires the inner membrane potential, and is mediated by mitofusins. Mol. Biol. Cell 13, 4343–4354.
Zuchner S., Mersiyanva I. V., Muglia M., et al. (2004) Mutations in the mitochondrial GTPase mitofusin 2 cause Charcot-Marie-Tooth neuropathy type 2A. Nat. Genet. 36, 449–451.
Bradbury J. (2004) Mitochondrial fusion protein mutted in CMT2A. Lancet Neurol. 3, 326.
Kijima K., Numakura C., Izumino H., et al., (2005) Mitochondrial GTPase mitofusin 2 mutation in Charcot-Marie-Tooth neuropathy type 2A. Hum. Genet. 116, 23–27.
Pich S., Bach D., Briones P., et al. (2005) The Charcot-Marie-Tooth type 2A gene product, Mfn2, up-regulates fuel oxidation through expression of OXPHOS system. Hum. Mol. Genet. 14, 1405–1415.
Beal M. F. (2002) Coenzyme Q10 as a possible treatment for neurodegenerative diseases. Free Radic. Res. 36, 455–460.
Zhu S., Stavrovskaya I. G., Drozda M., et al. (2002) Minocycline inhibits cytochrome c release and delays progression of amyotrophic lateral sclerosis in mice. Nature 417, 74–78.
Li M., Ona V. O., Guegan C., et al. (2000) Functional role of caspase-1 and caspase-3 in an ALS transgenic mouse model. Science 288, 335–339.
Klivenyi P., Ferrante R. J., Matthews R. T., et al. (1999) Neuroprotective effects of creatine in a transgenic animal model of amyotrophic lateral sclerosis. Nat. Med. 5, 347–350.
Beretta S., Sala G., Mattavelli L., et al. (2003) Mitochondrial dysfunction due to mutant copper/zinc superoxide dismutase associated with amyotrophic lateral sclerosis is reversed by N-acetylcysteine. Neurobiol. Dis. 13, 213–221.
Pattee G. L., Post G. R., Gerber R. E., and Bennett J. P. Jr. (2003) Reduction of oxidative stress in amyotrophic lateral sclerosis following pramipexole treatment. Amotroph. Lateral Scler. Other Motor Neuron Disord. 4, 90–95.
Drachman D. B., Frank K., Dykes-Hoberg M., et al. (2002) Cyclooxygenase 2 inhibition protects motor neurons and prolongs survival in a transgenic mouse model of ALS. Ann. Neurol. 52, 771–778.
Liu R., Li B., Flanagan S. W., Oberley L. W., Gozal D., and Qiu M. (2002) Increased mitochondrial antioxidative activity or decreased oxygen free radical propagation prevent mutant SOD1-mediated motor neuron cell death and increase amyotrophic lateral sclerosis-like transgenic mouse survival. J. Neurochem. 80, 488–500.
Zheng C., Nennsmo I., Fadeel B., and Henter J. I. (2004) Vascular endothelial growth factor prolongs survival in a transgeic mouse model of ALS. Ann. Neurol. 56, 564–567.
Li B., Xu W., Luo C., Gozal D., and Liu R. (2003) VEGF-induced activation of the P13-K/Akt pathway reduces mutant SOD1-mediated motor neuron cell death. Brain Res. Mol. Brain Res. 111, 155–164.
Ellis A. C., and Rosenfeld J. (2004) The role of creatine in the management of amyotrophic lateral sclerosis and other neurodegenerative disorders. CNS Drugs 18, 967–980.
Andreassen Q. A., Jenkins B. G., Dedeoglu A. et al. (2001) Increases in cortical glutamate concentrations in transgenic amyotrophic lateral sclerosis mice are attenuated by creatine supplementation. J. Neurochem. 77, 383–990.
Zhang W., Narayanan M., and Friedlander R. M (2003) Additive neuroprotective effects of minocycline with creatine in a mouse model of ALS. Ann. Neurol. 53, 267–270.
Drory V. E. and Gross D (2000) No effect of creatine on respiratory distress in amytrophic lateral sclerosis. Amyotroph. Lateral Scler. Other Motor Neuron Disord. 3, 43–46.
Derave W., Van Den Bosch L., Lemmens G., Eijnde B. O., Robberecht W., and Hespel P. (2003) Skeletal muscle properties in a transgenic mouse model for amyotrophic lateral sclerosis: effects of creatine treatment. Neurobiol. Dis. 13, 264–272.
Shefner J. M., Cudkowicz M. E., Schoenfeld D., et al. (2004) A clinical trial of creatine in ALS. Neurology 63, 1656–1661.
Keep M., Elmer E., Fong K. S., and Csiszar K. (2001) Intrathecal cyclosporin prolongs survival of late-stage ALS mice. Brain Res. 894, 327–331.
Kirkinezos I. G., Hernandez D., Bradley W. G., and Moraes C. T. (2004) An ALS mouse model with a permeable blood-brain barrier benefits from systemic cyclosporine A treatment. J. Neurochem. 88, 821–826.
Jacobs H. T. (2003) The mitochondrial theory of aging: dead or alive? Aging Cell 2, 11–17.
Beal M. F. (1995) Aging, energy, and oxidative stress in neurodegenerative diseases. Ann. Neurol. 38, 357–366.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Bacman, S.R., Bradley, W.G. & Moraes, C.T. Mitochondrial involvement in amyotrophic lateral sclerosis. Mol Neurobiol 33, 113–131 (2006). https://doi.org/10.1385/MN:33:2:113
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1385/MN:33:2:113